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Abstract 
Glioblastoma multiforme (GBM) is an extremely aggressive type of glioma. Life 
expectancy is around two years after diagnosis, due to recidivism and to the 
presence of the blood brain barrier (BBB) restricting the amount of drugs which arrive 
at the residual cancer cells, thus contributing to chemotherapies failure. To overcome 
the impediment imposed by the BBB, we have investigated the use of 
nanotechnologies in synergy with radiotherapy as a prospective strategy for GBM 
treatment. We have used poly(lactic-co-glycolic acid) (PLGA) nanoparticles (PNP) 
conjugated to the peptide chlorotoxin (CTX), which has been shown to recognize and 
selectively bind to glioma cells. Silver nanoparticles have been encapsulated inside 
the functionalized nanoparticles (Ag-PNP-CTX), to allow detection of cellular uptake 
and quantification by means of confocal microscopy, both in vitro and in vivo. In vitro 
experiments, involving 3 different human glioblastoma cell lines, have shown that the 
cytoplasmic uptake of Ag-PNP-CTX is higher than that of non-functionalized 
nanoparticles. Experiments performed in vivo have shown high efficiency of Ag-NP-
CTX particles in targeting tumor cells; however, they have been shown to be scarcely 
able to cross the blood brain barrier at the healthy brain level, where scattered 
metastatic cells are present too. A single x-rays administration on the whole brain, 
carried out twenty hours before the injection of the nanoparticles, has been shown to 
increase the levels of expression of the CTX targets MMP-2 e ClC-3. Moreover, 
through an alteration of BBB permeability, it has been shown to potentially increase 
the quantity of internalized Ag-PNP-CTX also in dispersed cells, and to lead to 
significant results in inhibiting tumor growth in vivo. Notably, the administration of Ag-
PNP-CTX to irradiated tumor cells decreases the MMP-2 extracellular activity. By 
targeting scattered GBM cells and limiting MMP-2 activity, the synergic use of 
nanovectors conjugated with CTX and radiotherapy may represent an efficient 
therapeutic approach to GBM treatment. 
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1 Introduction 
1.1 Brain tumors 
Cases of primary malignant central nervous system (CNS) tumors constitute about 
2% of all cases of cancer [1]. 
Intracranial tumors can arise in adulthood and children or adolescents. They are the 
primary cause of death in children and the third primary cause of death for 
adolescents and adults [2, 3]. 
Primary CNS tumors comprise a wide range of pathological entities, each with a 
distinct natural history. CNS tumors can be classified as gliomas or non-gliomas [4]. 
Non-gliomas can originate from different brain tissues. For example meningiomas, a 
benign form of cancer, originate in the dura [5], while medulloblastoma [6], and 
cerebral neuroblastoma are classified as primitive neuroectodermal tumors [7]. 
Tumors originating from glial cells are called gliomas and represent about 80% of all 
malignant CNS tumors [8]. The most common gliomas are astrocytomas, including 
glioblastoma multiforme (GBM), oligodendrogliomas, and ependymomas [8-9]. 
A brain tumors classification drafted in 2007 by World Health Organization (WHO), 
also supplies objective criteria to categorize histologic grade of head cancer: 
 Low grade I tumors are characterized by lesions with low proliferative 
potential (i.e. pilocytic astrocytomas). 
 Low grade II is a type of cancer with low proliferative potential with 
infiltration tendencies and cytologic anomaly (i.e. astrocytoma). 
 High grade III tumors are characterized by lesions with anaplastic evidence 
and mitotic activity (i.e. anaplastic astrocytoma).  
 High grade IV tumors are characterized by lesions with nuclear anomaly, 
cellular pleomorphism, mitotic activity, microvascular proliferation and/or 
necrosis (i.e. GBM) [10-11].   
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Astrocytic tumors can be distinguished into two distinct categories based on how they 
interact with their immediate microenvironment, namely diffuse and localized 
astrocytomas. Localized astrocytomas have a circumscribed pattern of growth and 
limited invasive potential, whereas diffuse astrocytomas are characterized by their 
cellular infiltration of the peritumoral margin and disperse to distant sites, regardless 
of tumor grade [12-13]. Although astrocytic tumors of all three higher grades are 
invasive, the higher-grade tumors (i.e., grades III and IV) are progressively more 
proliferative and result in a shorter time to tumor recurrence than lower-grade tumors 
[8]. All glial tumors (except for [WHO grade I]) recur at high frequency after treatment 
with surgery, radiation, and chemotherapy and are essentially incurable [14]. 
1.2 Glioblastoma Multiforme 
1.2.1 Introduction 
Glioblastoma multiforme (GBM) is the most common primary brain neoplasia which is 
mostly found in 55-years adults, but which can arise in younger (children and 
adolescents) population too. It is among the deadliest of all human cancers with an 
overall 5-year survival rate of less than 3,3% [15]. It represents 12-15% of all 
intracranial neoplasia and 60-75% of the astrocytic tumors [16]. GBM can be a 
primary tumor, if it arises without previous evidence of disease, otherwise it can 
develop from lower grade gliomas (secondary GBM) [17]. 
GBM is characterized by remarkable biological heterogeneity and poor response to 
currently available treatments [18]. Even if the tumor responds well to initial 
treatments and is seemingly disappeared on follow-up scanning, recurrence is 
inevitable locally, often within 2 cm of the original tumor, or at distant sites within the 
brain [20]. The median survival time of GBM patients with the best currently available 
therapy is approximately 14,6 months [15].  
The causes of treatment failure, disease progression, and recurrence flow from the 
biological features of GBM. Critical GBM peculiarity is the high level of proliferation, 
invasiveness, angiogenesis, stemness [19]. 
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1.2.2 Invasion and metastatic potential 
GBM is a highly proliferative and invasive type of cancer [18]. Even though it rarely 
metastasizes out of the CNS, GBM cells have an excellent infiltrating ability at the 
brain level [21]. Changes of shape, volume, morphology and the formation of 
membrane protrusions allow cancer cells to invade brain parenchyma, through the 
perivascular space or through the extracellular matrix (ECM) [22]. These actin rich 
protrusions, termed invadopodia in cancer cells [23], constitute a key step in invasion 
processes: they help cells move forward and permit them to attach to the ECM and 
degrade it [24]. The invadopodia ability to digest ECM is attributed to the presence of 
ECM degrading enzymes such as matrix-metalloproteinases (MMPs). Furthermore, 
MMPs can be released from protrusions to facilitate invasion [25]. Indeed, there is 
evidence of involvement of MMPs in ECM degradation and of overexpression of 
several MMPs in cancer cells, including glioma cells [26]. Glioma cells movements is 
determined by ECM deterioration, and promoted by the presence of the chloride 
channels that actively contribute to changes in cell shape and volume [27]. 
1.2.3 MMP2 
MMPs constitute a family of proteinases which includes 22 enzymes [28-29-30-31]. 
MMPs named according to the order of their discovery and can be distinguished into 
different subclasses on the basis of their substrate specificity (collagenases, 
gelatinases, matrylisn, metalloelastase, enamelysin) [32]. In the CNS, over 10 
different types of MMPs have been found [33] and their role in CNS pathology has 
been demonstrated [34] In particular, MMP2 (72 KDa gelatinase type A) is involved in 
cancer progression, invasion, metastasis, angiogenesis, and survival [35, 36, 37].   
 
MMP2 is a Zn+2 dependent endopeptidase and, similarly to all MMPs, is synthesized 
and secreted as zymogen form and its regulation occurs at different levels [38]. 
Whole activation is allowed by activating factors that cause pro-peptide domain 
removal (see Figure 1 for more detailed mechanisms explanation) [38-39]. 
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Figure 1. Schematic representation of MMP2 domains. Pre-domain N-terminal signal 
sequence that directs the protein to the endoplasmic reticulum. Pro-domain that contains a 
highly conserved sequence with unpaired cysteine sulfhydryl groups that interact with the 
active site zinc maintaining the MMP2 in latent form (the cysteine switch). Catalytic domain 
contains the conserved zinc-binding region, three gelatin-binding fibronectin types II repeats 
and also have a series of three head-to-tail cysteine-rich repeats within its catalytic domain. 
These inserts resemble the collagen-binding type II repeats of fibronectin and are 
indispensable to bind and cleave collagen. Hemopexin domain is folded into a four-bladed 
propeller structure. The hemopexin domain is required for TIMP2 (Tissue Inhibitors of 
Metalloproteinases2) binding (via the C-terminal), the binding of substrates, membrane 
activation, and some proteolytic activities. Figure adapted from Sternlicht et al., 2001 [39].  
The regulation of MM2 is higly regulate, in GBM context can occur an over 
expression of MMP2 and its activity [40-41]. MMP2 is regulated at different levels:  
1. transcription level 
2. post-translational level 
3. interaction with tissues inhibitors  
1. MMP2 transcription level can be modulated by many substances such as 
fibronectin in many types of cancer cells including gliomas [42-43-44-45] by complex 
signals induced by ECM proteins like osteopontin, various cytokines including IL-8 
that is overexpressed in glioma cell [46] by epigenetic mechanisms [47-48], and also 
by growth factors such as EGF [49]. 
2. MMP2 activity regulation can occur at post-translational level due to different 
proteases [50] and by phosphorylation status [51]. MMP2 contains 29 potential 
phosphorylation sites a has been shown that the phosphorylation status of MMP2 
significantly affects its enzymatic properties improving his activity [51-52].  
3. MMP2 activity is regulated by its interaction with tissue inhibitors of 
metalloproteinases (TIMPS) [53-54]. TIMP2 is specific inhibitor of MMP2 (see figure 
2) [55]. However, TIMP2 have a double role in MMP2: inhibition and activation [56].   
 
Pro Catalytic
Hemopexin
H
S S
Pre F F F Zn
SH
Gelatin-binding MMPs
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Figure 2. MMP14 - TIMP2 – MMP2 ternary complex schematic representation. TIMP2 
bind through its N-terminal three loops to the MMP14 catalytic domain. Figure adapted from 
Murphy et al., 1997 [56]. 
 
In the case of TIMP2 as MMP2 inhibitor, in very general terms, it is possible to 
explain MMP2 regulation on the basis of TIMP2 expression levels as follows. 
 
- High TIMP2 levels: MMP2 is inhibited. At the membrane level, TIMP2, pro- 
MMP2 and type 1-matrix metalloproteinase (MMP14)  form a ternary complex 
[57] (Fig. 2); two MMP14 molecules inhibit MMP2 activation with the result in 
pro-MMP2 recruitment and accumulation [57]. 
 
- Low levels of TIMP2: MMP2 is activated. There is not a MMP14-MMP2 ternary 
complex and MMP14 can mediate MMP-2 activation. A free MMP14 molecule 
cleaves partially MMP2 the pro-peptide region [56]. Complete pro-peptide 
removal is due to the action of the MMP2 intermediate or to other active MMPs 
(“stepwise activation” mechanism) [58].  
In normal tissues which express low levels of MMP2 and MMP14, even low amounts 
of TIMP2 are sufficient to inhibit MMP2 activation [57]. However in GBM cells, where 
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MMP2 and MMP14 are upregulated [57], the amount of TIMP2 is the main 
responsible for balancing MMP2 activation level [59]. 
GBM cells, such as U87MG cell line that overexpress MMP2 and MMP14 but secrete 
TIMP2 at low levels, are able to induce low MMP2 activation [57]. 
In cases of higher upregulation of TIMP2 level expression, MMP14 /TIMP2/proMMP2 
complexes are more often found at the membrane level resulting in an increased 
presence of MMP2 active form [57]. 
 
MMP2 is upregulated in high-grade gliomas, such as GBM, whereas its level of 
expression is lower in lower-grade types [41].  
A correlation between MMP2 level of expression and the ability of different glioma 
cells to migrate across a synthetic basement membrane in vitro has been established 
[40]. 
MMP2 invasive properties arise from its ability to digest a large number of ECM 
components including type I, II, III; IV, V and XI collagens, laminin and aggrecan core 
protein [60]. 
1.2.4 CLC-3 
The family of chloride channels (ClCs) is a highly conserved cluster of voltage-gated 
channels and has 9 members [61]. ClCs are involved in the regulation of cell volume, 
control of electrical excitability, trans-epithelial transport [63], and cell cycle 
progression [64]. The role of ClCs in bypassing cell cycle checkpoint can explain their 
implication on the oncogenesis process [65-56]. 
The CIC-3 chloride channel, in particular, is normally expressed in the SNC in the 
synaptic vesicles [67-68], in the membranes of the late endosomes [69-70] and also 
in glial cells [71]. Being up-regulated in glioma membranes [72-73], it has been 
supposed to be actively involved in the glioma cells invasive process [74] and to play 
an important role in facilitating migrating behavior of GBM cells [27].  
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Figure 3 - Schematic representation of 
ClC-3 mediated glioma cells motility 
processes. a) Stimulation of G protein-
coupled receptors (GPCRs) causes an 
increase of intracellular Ca2+ concentration 
in glioma cells, leading to Ca2+-dependent 
activation of Ca2+/calmodulin-dependent 
protein kinase II (CaMKII)-dependent ClC3 
and KCa3.1 channel opening. This leads to 
the efflux of Cl− and K+, obligating water to 
flow down its osmotic gradient and leave the 
cell. b) The consequent decrease in 
cytoplasmic volume enables it to squeeze 
into adjacent spaces and to pass barriers. c) 
The successive ion influx mediated by the 
Na+–K+–Cl− cotransporter 1 (NKCC1) and 
the acid-sensing ion channel 1 (ASIC1) 
causes water influx and, consequently, 
cytoplasmic volume increase. Figure 
adapted from Cuddapah et al., 2010 [75]. 
 
ClC-3 channels are crucially involved in the motility of glioma cells. As shown in 
Figure 3, cell movements are caused by water efflux due, among other factors, to the 
opening of the overexpressed ClC-3 channels. These events cause a decrease of 
cytoplasmic volume, making the cell able to squeeze into small spaces. The 
successive volume increase, due to influx of Na+, K+ and 2Cl– causing, in turn, water 
influx, enables the cell to move forward and pass barriers (Figure 3) [72,75].  
ClC-3 can facilitate invasiveness also by forming complexes with MMP2, TIMP2, 
MMP14, ανβ3 integrin, BK potassium channel and aquaporin-4 (AQP-4) in lipid rafts 
of invadipodia [76]. 
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1.3 Therapy of Glioblastoma Multiforme  
1.3.1 Introduction 
Standard GBM treatment consists of surgical resection followed by 6 weeks of 
radiotherapy with concomitant Temozolomide (TMZ) and by adjuvant TMZ as single 
agent [77]. 
Even when treated aggressively, GMB recurs and this is the cause of the poor 
prognosis. The area of recurrence develops at the borders of the surgical cavity, over 
90% of the cases within 2 cm of the original tumor, or at distant sites within the brain 
at later stage  [20].  
In case of recurrence, a limited number of treatments are available. 
Factors that can influence the therapeutical response are the following: patient age, 
tumor location, the Karnofsky Performance Status, lesion radiologic characteristics, 
amplitude of surgical resection, proliferation index, the metilation status of the 
promoter of gene for the metil-guanin-metil-transferasi (MGMT) and the status of 
IDH1/2 [78,79].   
1.3.2 Surgery  
Surgery is the early therapy step for all patients with primary brain cancer. Surgery 
can be curative for many benign tumors, such as meningiomas [80] but not so 
efficient as far as high grade gliomas are concerned. This failure is due by infiltrative 
nature of high grade gliomas that makes complete surgical removal impossible [81]. 
Surgical removal currently is the most effective treatment: survival time is correlated 
with the amount of resected tumor mass [82].  
In high grade gliomas cases, the goal of surgery is limited to eliminating neurologic 
symptoms due by cancer mass, to obtaining histologic diagnosis from the biopsy, to 
promoting reduction of cancer cells, and to treating hydrocephalus if present [82]. 
1.3.3 Radiotherapy 
Ionizing radiations are currently employed on the part of the brain which has been 
subjected to surgical resection [15].   
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The main role of radiotherapy (RT) is to damage DNA of infiltrating cells which cannot 
be eradicated by the surgery, as well as of cells spreading from distant sites of 
surgery [83]. RT is also effective in blood-brain barrier (BBB) disruption in dose time 
dependent [84]. This phenomenon can lead to a more effective chemotherapic drugs 
(especially of hydrophilic compounds) delivery [85].    
Different approaches have been recently developed in order to improve therapy 
effectiveness, including: 
 
- Fractionated radiotherapy. It consists in fractionating the total amount of 
therapeutical radiation into several doses. For example, a total dose of 60 Gy 
fractionated into 2 Gy doses for 30 days after surgery [20,77]  are administred 
on the part subjected to surgery and on the immediate surroundings (2 cm 
over the surgical border) [86]. 
- Ultrafractionated radiation therapy. It is a system consisting of radiotherapy 
low doses (<0.75 Gy) administered several times daily (3 daily doses every 4 
hours for 5 days per week). The treatment lasts 6–7 weeks (90 fractions for a 
total of 67.5 Gy) [86]. 
- Stereotactic radiosurgery (SRS). SRS is a form of radiation therapy that 
consists in high-power energy administration (24 Gy, 18 Gy, or 15 Gy) focused 
on a small area (diameter between 20-40 mm in diameter) [87]. SRS is usually 
used for the treatment of one to few  brain metastases in a single session or 
when tumor cannot be removed [88]. 
- Stereotactic radiotherapy. Stereotactic radiotherapy is a treatment used for 
small tumors which are impossible to eradicate by surgery. By means of a 
linear accelerator (LINAC), low doses of ionizing radiations are delivered from 
different angles converging in a specific  small area (diameter between 20- 40 
mm in diameter) [87]. The result is a high amount of radiations delivered in a 
precise area minimizing damage to healthy surrounding tissues. Generally, the 
treatment is fractionated into 3 and 30 daily doses [89]. 
The effectiveness of RT for high grade gliomas has been confirmed by many 
experimental studies [15, 90-94]. For example, in survival times after surgery and 
radiotherapy, radiotherapy only, surgery only, and no therapy have been assessed 
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through univariate, multivariate, and Kaplan–Meier analyses: the results have been 7 
months, 4 months, 2 months, and 1 month, respectively. Nevertheless, there are also 
adverse effects [90]. One of the most significant ones is the tendency to induce 
overexpression of MMP2 [95] and MMP9, as well as to increase the expression of 
TIMP2 [96, 97] all molecules involved in invasivity processes. In principle, therefore, 
radiations can increase the probability of recidivism [98]. 
1.3.4 Chemotherapeutics 
TMZ, administered with RT, is the most effective drug for GBM treatment. As there is 
no equally effective alternative therapy in case of drug resistance [95], the many 
clinical trials are under investigation. Some of them consist in subjecting t he patient 
to a variety of dosing schedules in which the duration of exposure and the cumulative 
dose of TMZ is increased, with the purpose of improving antitumor activity and 
overcoming resistance [99]. Other clinical trials involve targeted therapies in 
combination with cytotoxic chemotherapy and radiotherapy in order to bypass tumor 
resistance [100]. These include Epidermal Growth Factor Receptor Inhibitors, 
Platelet-derived Growth Factor Inhibitors, Vascular Endothelial Growth Factor/ 
Vascular Endothelial Growth Factor Receptor Inhibitors, Mammalian Target of 
Rapamycin Inhibitors, Protein Kinase C, RAF-MEK-ERK, and Integrin Inhibitors. Most 
of the targeted therapy validate on phase II clinical trials have not given benefits in 
survival ratio. Better drugs strategies are represented by the combination of 
multitargeted drugs with cytotoxic chemotherapy and radiotherapy [for a review on 
targeted therapies for GBM see100]. 
1.3.5 Resistance to radiotherapy and chemotherapy 
Recidivism is due to the fact that not all malignant cells are totally removed by the 
currently available pharmacological treatments. 
The reasons of drug failure can be grouped as follows: 
  
1) intrinsic biology of GBM cells; 
2) GBM micro-environment; 
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3) Chemoresistence induced by pharmacological treatment. 
As far as the first point is concerned, GBM cells show mutations which ultimately 
decrease the effectiveness of the current therapies. The overexpression of factor 
tyrosine kinase receptor (TKR) pathways and the upregulation of several growth 
factors such as EGF contribute to lead resistance to drugs [101].  
In addition the presence of the ATP-binding cassette (ABC) transporter family (P-
glycoprotein, P-gp), and of the multi-drug resistance protein (MRP) [102], reduce the 
drugs efficacy pushing drugs out of the cell [103]. Moreover, the presence of integrins 
β1 [104], αvβ3, and αvβ5 [105] contrast the cytotoxic effects of the drugs by 
facilitating cell proliferation and preventing apoptosis [106]. Other element 
responsible for drug failure is the presence of glioblastoma staminal cells (GSCs) 
[107]. GSCs resistance to therapy is higher than that of more differentiated GBM 
cells, both in vivo and in vitro [108]. This is due, for example, to the upregulation in 
GSCs of anti-apoptotic proteins (miR-21 and Bcl-2 for example) [108] and by 
upregulation of DNA repair ability [109,110]. 
Drug failure can be caused by microenvironmental factors too [111]. Some areas in 
the microenvironment are hypoxic. GBM cells in hypoxic areas show low amount of 
proliferation and have a slower metabolism; therefore, they are non-responsive to the 
anti-cancer drugs which are effective on highly proliferating cells [112]. Moreover, 
they show an increase of pro-survival responses induced by transcription of several 
genes, which include the family of hypoxia inducible factors (HIFs) [113].  
A third sort of factors responsible for drug failure concern the specific target of the 
drug and the effects of the drug in promoting resistance. These factors can be 
intrinsic or acquired [113]. Intrinsic factors are related to mutations of the specific 
molecules. For example, overexpression of the DNA repair protein O6-methylguanine 
methyltransferase (MGMT) makes TMZ ineffective, similarly to every other alchilating 
agents [114]. Acquired resistance occurs when initially responsive cells progressively 
become non-responsive [114-115].  
Drug resistance can be also caused by radiotherapy (ref): ionizing radiations can 
induce survival of cancer cells by increasing the level of expression of several growth 
factors and proteins such as the epidermal growth factor receptor (EGFR) [116] and 
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vascular endothelial growth factor (VEGF) [117], which are known to have anti-
apoptotic effects [101]. 
1.4 The blood brain barrier 
1.4.1 Introduction 
One of the major limitations of chemotherapy in brain tumors is represented by the 
inefficient passage of drugs across the blood brain barrier (BBB). For this reason, 
drugs cannot reach niches of GBM cells infiltrated in the healthy parenchima and 
protected by the BBB [118-120]. Moreover, BBB cells tend to extrude drugs due to 
the action of P-glycoproteins (Pgp/ABCB1), which are multidrug resistance-related 
proteins [121] 
BBB is an active, dynamic anatomical-functional unit which regulates exchanges 
between blood vessels and the brain parenchima [120]. It plays a key role in brain 
homeostasis and provides protection against many toxic compounds and pathogens 
[121]. In addition, the BBB regulates and supply nutrients to the brain by specific 
transport systems [122].  
BBB is made by cellular and non-cellular components [123]. The cellular components 
include neurons, microglia, pericytes, astrocytes and endothelial cells (ECs) (Figure 
4) [124]. 
ECs compose the SNC endothelium and constitute key structural components of the 
BBB [125]. ECs have an uniform thickness, low pinocytotic activity [126,127] and 
there is no fenestration between adjacent cells, thus leading to a considerable 
reduction of the paracellular diffusion of hydrophilic solutes [128]. Due to these 
features, ECs are able to strictly regulate the selective transport of substances from 
blood to brain and from the parenchyma to blood [129]. 
Astrocytes play a fundamental role in the functionality of BBB. Their endfeet are 
apposed to the BBB endothelium and to the basement membrane, thus crucially 
contributing to maintaining its integrity [128]. 
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Astrocytes also crucially contribute to proteoglycan synthesis and to the subsequent 
increase in brain microvascular endothelial cells (BMVEC) charge selectivity; they 
also play an important role in every BBB function and modulation [129]. 
The non-cellular component is composed by agrin, heparan sulphate proteoglycan, 
an extracellular matrix compound [130], and by the basement membrane which is an 
essential BBB component surrounding BMVEC and securing the BBB cells in place 
[131]. BMVEC, pericytes and astrocytes all generate and maintain the basement 
membrane. The basement mebrane is constituted by fibronectin, laminin l a 
noncollagenous glycoprotein [132,133] collagen, and elastin [134].  
 
 
 
Figure 4. Schematic structure of the main BBB components. Neurons regulate the 
function of blood vessels by triggering expression of EC enzymes. Microglia contributes to 
BBB properties by interacting with EC. Pericytes are physically associated with the 
endothelium and synthesizes most elements of the basement membranes, such as some 
kinds of proteoglycans and laminal proteins. Figure adapted from Abbott et al., 2010 [135]. 
Brain microvascular characteristics result from interactions of these cells with the 
basement membrane [135,136]. All these cells and basement membranes constitute 
the neurovascular unit (NVU) which is essential for physiological CNS function [123]. 
  
17 
 
1.4.2 Tight junctions 
Critical components of The BBB are represented by tight junctions (TJs or “zonulae 
occludentes”) present between adjacent endothelial cells. They play a pivotal role in 
BBB selective permeability by reducing paracellular diffusion of polar solutes and 
macromolecules [137]. 
Tight junctions consist of a protein complex including occludin, claudins 3, caludins 5 
and junctional adhesion molecules (JAMs) [136]. Claudins 3 and 5, which constitute 
the most effective factor in limiting paracellular diffusion, associate and bind to one 
another across the intercellular scaffolding and regulatory proteins ZO-1, ZO-2, ZO-3 
and cingulin (Figure 5) [134]. 
Some properties of the BBB tight junctions are highly sensitive to stimuli coming from 
the microenvironment, and can be modulated “minute-to-minute” resulting in 
functional changes of paracellular pathways [138]. Claudins and occludins 
configurations change modifying the tight junctional properties.  
 
  
Figure 5. Schematic structure of BBB tight junctions. A) Tight junctions comprise 
occludin, claudins 3 and  claudin 5. Claudins and occludins link the scaffolding proteins ZO-
1, ZO-2 and ZO-3, connected by means of cingulin dimers to actin/myosin. B) Transport 
across the BBB. (a) Passive diffusion of lipophilic solutes. (b) Active efflux carriers ABC 
transporters, such as Pgp and BCRP, can stop solutes and pump them out of the cell. (c) 
Carrier mediated influx via solute carriers (SLCs) can be passive or active and can transport 
many essential polar molecules such as glucose, amino acids and nucleosides into the CNS. 
(d) transcitosys receptor mediated (RMT) mediates transport of various macromolecules, 
including peptides and proteins, across the endothelium (transcytosis). (e) Leukocytes cross 
the BBB either by a process of diapedesis through the endothelial cells, via CD99 receptor, 
or through modified tight junctions. Figure adapted from Begley et al., 2003 [138]. 
A B
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1.4.3 Blood–brain barrier in glioblastoma multiforme 
An important feature of GBM is its high grade of vascularization, due to its tendency 
to carry out angiogenetic processes [139]. Unlike normal cerebral vessels, GBM neo 
vessels are characterized by morphological and functional alterations [140].  
The most common characteristics of GBM blood vessel are [140]: 
- formation of fenestrations; 
- alterations of the tight junctions;  
- number of caveolae and mitochondria;  
- thickness of the subendothelial basal lamina;  
- increase of the perivascular space. 
 
 
Figure 6. Schematic view of the relation between glial endfoot and ECs. A) Astrocytes 
endfoot in healty BBB. Astrocytes endfeet are closely associated with endothelial cells (ECs) 
.-dystroglycan is a membrane protein in contact with -dystroglycan (outside) and the 
dystrophin–dystroglycan complex (DDC; inside). -syntrophin binds to AQP4. AQP4 can 
arrange in complexes named orthogonal arrays of particles (OAPs). Agrin binds with -
dystroglycan,. However, it is connected to AQP4 by an -dystroglycan to -syntrophin 
bridge. K+ channels in the endfeet co-localize with aquaporin 4 (AQP4) (K+ and AQP4 have 
similar conductivity distribution. K+ ions, whose extracellular concentration is increased by 
neuronal activity, are taken up by astrocytes; K+ uptake is accompanied by water efflux 
through AQP4. The correct positioning of K+ channels and AQP4 is due to the presence of 
agrin, an heparan sulphate proteoglycan, extracellular matrix compound and laminin 
noncollagenous glycoprotein . B) Astrocytes endfoot in glioblastoma BBB. MMP3 cleaves 
agrin and MMP2/9 cleave dystroglycan. MMPs digestion leads to a loss of OAPs and to a 
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loss of AQP4-polarity due to the loss of DDC scaffolding quality. Figure adapted from 
Wolburg et al., 2012 [140]. 
BBB vessels can be destroyed by the presence of GBM cells. MMPs, upregulated in 
GBM cells, are involved in BBB disruption [141-142]. Similarly to MMP9 and MMP2, 
MMP-3 are upregulated in GBM [141]. MMP3 cleaves agrin and MMP2 and MMP9 
destroy dystroglycan at the level of astrocytic endfoot (Figure 6) leanding an 
alteration of potassium and water channel [140]. The result is the detachment of 
astrocytic endfeet from the vessel and from the basal lamina, the disruption of TJs of 
ECs cells and the breakdown of the BBB by runaway influx of extracellular water into 
the brain parenchyma (vasogenic edema) [140,141]. 
The MMPs activity damages the ECM too resulting in increase of thickness and agrin 
downregulation [142]. The basement membrane digestion contributes to TJs 
deregulation [143,144]. Accordingly, extracellular matrix disruption is strongly 
associated with BBB permeability increase not only in GBM but also in several 
pathological situations [144]. 
1.4.4 Effects of ionizing radiation on the BBB 
Ionizing radiation can impair the integrity of the BBB [145]. It has been shown that in 
a murine model, a single dose of 0,1 Gy, 2 Gy or 10 Gy is able to increase the BBB 
permeability determining an extravasation of Albumin. The time window of BBB 
opening depends on age, on dose and on administered dose number of radiations 
[145, 146]. 
Radiations cause permeability of BBB modulation, leading changes in morphological 
structures of ECs cells and surrounding vessel astrocytes, and leading senescence 
in ECs cells [146]. The increased permeability of BBB caused by radiations is 
associate with disruption of TJs between adjacent ECs in vitro [146].  
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1.5 Polymeric nanocarriers 
1.5.1 Introduction 
Given the complexity for most drugs to reach the brain and bypass the BBB, the use 
of nanotechnological approaches, and in particular nanoparticles, has been proposed 
as promising and alternative therapeutic strategy [147].  
Nanotechnology has been suggested for selectively deliver contrast imaging and 
anti-cancer agents into tumor cells with the advantage of not affecting normal healthy 
tissues and cells [148].  
Nanoparticles can vary in chemical composition in size and shape and their surface 
may be modified [149]. Different compositions confer to nanoparticles specific 
abilities; for example the peptides addition on the nanoparticles external surface can 
address them to a specific target [149]. Nanoparticles can be achieved to permeate 
the brain bypassing through endothelial cells by transcytosis, opening the tight 
junctions of brain capillaries or adhering to the vessels walls and crossing the BBB by 
virtue of osmosis [149, 150]. 
Nanoparticles can act as a tumor-specific drug delivery vehicle working as carriers. 
Drugs can be encapsulated within the nanocarrier which can be shaped as a cage, a 
shell, a bubble, or as other kinds of forms [151]. 
Nanocarrier-based drug delivery into the tumor occurs through passive and active 
targeting [152]. Passive targeting is mediated by the inherent features of the tumor 
itself to retain drug-carrying nanoparticles and it is due to the increased permeability 
and retention (EPR) effect due by fenestrated angiogenic vessels [153]. Tumor blood 
vessels, contrary to normal, have 600 to 800 nm wide gaps between adjacent 
endothelial cells, leading to a faulty vascular system enabling nanoparticles to 
extravasate into the extravascular area and gather into tumor tissues. EPR effects 
cause a 10-fold increase in drug retention when nanoparticles are deployed as 
delivery vehicles compared with free drug alone [154]. One of the main pivotal factors 
causing EPR effects is the particle size. A particle size of 100-200 nm results may be 
optimal for in vivo targeting delivery based on EPR effects. 
Active targeting is strictly correlated with passive targeting and occurs only after 
passive accumulation of the particles within the tumor area. The binding of tumor-
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selective ligands to the cognate receptor present on the cell membrane significantly 
increases nanocarrier intracellular uptake and accumulation into cancer cells [154]. 
 
Several type of nanoparticles have been investigate as drug carriers including 
liposomes, dendrimers, gold nanoshells, nucleid acid-based nanoparticles, and 
polymeric nanocarriers [155]. 
1.5.2 Polymeric nanoparticles 
Polymeric nanoparticles (PNPs) are versatile carriers able to vehicle small molecules 
such as drugs or macromolecules such as nucleic acids and proteins [155]. Due to 
their chemical properties PNPs are able to enter in the cells, to elude degradative 
system by endosomal escaping once endocited into the cytoplasm and to be stable 
in the blood stream and prevent the release of embedded molecules leading low 
toxicity [156, 157, 158]. Currently, PNPs are commonly used for targeting therapeutic 
molecules to tumor cells. 
Polymeric vectors can be synthesized using different materials such as Polylactides 
(PLA), Polyglycolides (PGA), Poly(D,Llactic-co-glycolides) acid (PLGA), 
Polyanhydrides, Polyorthoesters, Polycyanoacrylates, Polyalkylcyanoacrylate, 
Polycaprolactone [155, 159]. 
In particular, Poly(lactic-co-glycolic acid)-block-poly(ethylene glycol)-carboxylic acid, 
(PLGA-b-PEG) block-copolymer is emerging as one of the most promising system for 
nanoparticles formation, drug loading and in vivo drug delivery applications. PLGA-b-
PEG is an amphiphilic polymer: the two polymer portions self-assemble during 
micelles formation, generating a targetable system (due to the presence of a COOH) 
in which the hydrophobic PLGA remains inside the micelles and the hydrophilic PEG 
goes outside creating a stabilizing shell. PEG- and PLGA- based polymers are 
known to be non-toxic GRAS (Generally Recognized As Safe) and FDA-approved 
[160, 161].   
Due to their tunable characteristics, controlled- and sustained-release properties, 
biodegradability and biocompatibility, polymeric PNPs represent a good strategy for 
the delivery of drug and/or diagnostic agents. PLGA-b-PEG copolymer has gained 
large attention in the past decade, since its approval by Food and Drug 
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Administration (FDA) for biomedical usage due to its ability to create micelles-like 
nanocarriers displaying an internal hydrophobic PLGA portion, suitable for entrapping 
lipophilic molecules, and an external hydrophilic PEG forming a stabilizing shell and 
increasing the half-life of the nanocarrier [160]. PLGA nanoparticles, which are 
typically 100-200 nm in diameter, even if locally administered by convectional 
enhanced delivery (CED), have limited mobility and diffusion by convection through 
the brain interstitial spaces [162,163], which are 38-64 nm in normal brain but show a 
superior mobility in tumoral regions in which the interstitial spaces is 70-100 nm 
[150,164].  
 
1.5.3 Chlorotoxin 
As mentioned before, nanovectors external layer, can be modified adding different 
molecules and among them even peptides that give to nanocarriers target specificity. 
One of the known peptides that target GBM cells is chlorotoxin (CTX). CTX is a 36-
residue peptide (MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPWLCR-NH2) [165] 
originally isolated from scorpio Leiurus quinquestriatus venom. CTX specifically and 
selectively binds to GBM cells [166,167] by recognizing its target molecules MMP2 
[76] and ClC-3 [168, 169], both abundantly expressed in glioma cells. MMP2 and 
ClC-3 can constitute a protein complex which is recognized by CTX; the bind of CTX 
with the MMP2/ClC-3 protein complex inhibit glioma cell invasion ability by inducing 
their endocytosis [76,169].  
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2 Materials and methods 
SYNTHESIS AND CHARACTERIZATION OF AG-PNP-CTX NANOVECTORS 
100 mg of PLGA-b-PEG-COOH (7 kDa-3 kDa) and AgNPs-1, both prepared as 
already reported 30, were admixed into 10 mL of dimethylformamide (DMF). This 
organic phase was mixed with 100 mL of ultrapure water under vigorous stirring, 
maintaining water/organic ratio 10/1 with a constant removal of the solution. The 
mixture was kept for 30 min. under vigorous stirring then washed and concentrated 
by using centrifugal filter devices (Amicon Ultra, Ultracell membrane with 100.000 
NMWL, Millipore, USA) to a final volume of 5 mL and finally filtered by using a 
syringe filters phenex-PES of polyether sulfone (26 mm, 0.20 μm, Phenomenex, 
Italy). To a suspension of the so obtained Ag-PNP (5 mL) in PBS (10 mL, 0.01 M), 
under magnetic stirring, a solution of N-hydroxysulfosuccinimide 2.3 mM (8.7 mL) 
and a solution of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 0.28 M (3.6 mL) 
was added. The reaction was carried out at room temperature for 15 minutes then 
50 μg of Chlorotoxin, dissolved into 1 mL of water, were added and left to react for 
24 hours. After that Ag-PNP-CTX were purified and concentrated to a final volume 
of 5 mL as previously described. Dynamic light scattering (DLS) analysis and ζ-
potential values were obtained with a Zetasizer Nano-S (Malvern) instrument, 
working with a 532 nm laser beam at 25 °C, using standard cuvettes or DTS1060C 
Clear Disposable zeta cells, and the results expressed as average of three 
measurements. Atomic absorption analysis was conducted in a SpectraAA 100 
Varian instrument, with opportune AgNO3 standards for calibration line. Final 
concentration of the suspensions was determined by gravimetric analysis by drying 
100 µL of solution at 130 °C for 24 hours then accurately weighting the residual dry 
matter amount. 
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CELL CULTURE 
Human-derived GBM cell line were grown in Minimum Essential Medium Eagle, 
Alpha Modification (MEM) (U87MG) or RPMI (A172, T98G) (Lonza, Basel, 
Switzerland) supplemented with 10% fetal calf serum (FCS, U.S. Origin, Gibco/Life 
Technologies), 100 U/ml penicillin and 0,1 mg/ml streptomycin. Cells were 
mantained at 37°C in a humidified incubator with 5% CO2.  
 
COMPETITIVE INHIBITION ASSAY 
U87MG and A172 cell lines were pre-treated for 2 hours with decreasing 
concentrations of the native CTX peptide 
(MCMPCFTTDHQMARKCDDCCGGKGRGKCYGPQCLCR-NH₂)  (H6086, Bachem, 
Bubendorf, Switzerland) followed by incubation with  targeted (Ag-PNP-CTX) or 
non-targeted (Ag-PNP) nanovectors at Ag concentration of 100 M for 16-18 hours 
(overnight). The intracellular accumulation of Ag nanoparticles (Ag-nps) was 
determined by confocal laser scanning microsco and 3D imaging analysis 
performed by IMARIS software (see below). 
 
MOUSE ORTHOTOPIC XENOGRAFTS 
Mouse experiments were carried out according to the protocol approved by Italian 
Minister of Health (protocol number 171/2013-B). CD-1 male nude mice, 6-8 weeks 
(Charles Rivers Laboratories, Calco, Italy) were housed in specific pathogen free 
animal house. Sterilized Water and rodent chow were given ad libitum. Mice were 
injected intracranially into the right striatum with U87MG cells at 5x104 cells/mouse 
or luciferase-transfected U87MGluc2 (gently provided by Laura Cerchia, CNR 
Naples, Italy) 105 cells/mouse. For intra-tumor nanovector accumulation analysis 
and quantification, U87MG-tumors were allowed to grow for 15 days, and then mice 
were subject to whole-brain single dose radiation (2 Gy). Ag-PNP-CTX were 
administered intraperitoneally at a dose of 1mg of dry matter 18 hours after 
radiations. Animals were euthanized 24 or 48 hours after nanovector injection. For 
immunofluorescence experiments intracardiac perfusion was carried out with 4% 
PFA. The harvested brains and organs were frozen and conserve at -80°C.  
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To study the antitumor effect of Ag-PNP-CTX, U87MGluc2-tumors were allowed to 
growth for 11 days, and then mice were randomized and divided in 4 groups: not 
treated animals (controls), animal treated only with Ag-PNP-CTX nanovectors, 
animal treated only with radiations, and animal treated with radiations and Ag-PNP-
CTX nanovectors. Mice were subject to whole-brain single dose radiation (2 Gy, 
T0). Ag-PNP-CTX administration started 18 hours after radiation treatment. Mice 
received 4 consecutive doses of Ag-PNP-CTX nanovectors (first 2 doses: 1 mg of 
dry matter; third and fourth doses: 0,5 mg of dry matter) at intervals of 48-72 hours.  
 
IN VIVO IMAGING OF INTRACRANIAL TUMORS 
An IVIS II Imaging System (Caliper LifeScinces- Perkin Elmer-Waltham, 
Massachusetts, USA) was used to take photograph and luminescent images setting 
an open filter and binning 8.  Exposure time was fixed at 1 minute and 5-10 images 
were acquired until maximum photon flux achievement. Ten minutes before 
acquisition, mice were administered intraperitoneal injection of D-luciferin (Perkin 
Elmer-Waltham), 150 mg/Kg, as a substrate for the luciferase enzyme. Images were 
captured and quantified with Living Image 4.3.1 software (Perkin Elmer-Waltham), 
based on equivalent regions of interest over the head. Analysis was carried out 
using the Living imaging software (Perkin Elmer - Waltham, Massachusetts, USA) 
setting binning 4 and “automatic ROI”  (thershold 50%) for all images. 
 
RADIATION TREATMENT 
Cells and mice were irradiated with a single dose of 2 Gy using an x-ray biological 
irradiator operating at 12 mA/190 kv (RADGIL, Gilardoni, Lecco, Italy). Cells were 
irradiated at a dose rate of 0,65 Gy/min. Mice were irradiated at a dose rate of 0,4 
Gy/min in an in-house designed lead irradiation jig that allowed only the head to be 
exposed and shielded the body.   
 
IN VITRO NANOVECTOR INTRACELLULAR UPTAKE 
U87MG, A172, T98G were seeded on glass cover slips (16 mm diameter) at a 
density of 15.000 cells/coverslip in the presence of 5% FCS. After 24h of culture, 
the cells were incubated  with  targeted (Ag-PNP-CTX) or non-targeted (Ag-PNP) 
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nanovectors at Ag concentration of 100M for 16-18 hours (overnight). One hour 
before cell fixation, Syto Blue 45® fluorescent dye (Life Technologies Corporation, 
Carlsbad, Ca, USA) was added to the medium (1:1000). After three washes in 
Dulbecco’s Phosphate Buffered Saline (PBS) (Sigma-Aldrich, St. Louis,MO, USA), 
cells were fixed in 4% paraformaldehyde for 15 min at room temperature. Glasses 
were mounted with a PBS/Glicerol (Sigma-Aldrich, St. Louis, MO, USA), mixture 
(1:1) added with DAPI (Sigma-Aldrich, St. Louis, MO, USA), fluorescent stain 
1:40.000. 
 
IMMUNOSTAINING 
Before immunostaining fixed 10-micron-thick frozen brain section were heat antigen 
retrieved in Sodium Citrate (pH=6). Unspecific binding was blocked with 10% horse 
serum (Sigma) diluted in PBS/Triton 0,1% (1 hour). Primary antibodies against 
human-nestin clone 2C1.3A11 (1:250 1h RT) (Abcam), human-MMP-2 (1:100 1h 
RT) (Sigma/Prestige Antibodies), human-ClCN3 (1:100 1h RT) (Cell Signaling 
Technology, Beverly, MA,USA), human-LAMP1 (BD Bioscience) (1:100 1h RT)  and 
mouse-claudin-5 (1:600 24h 4°C) (Millipore) were employed at same experimental 
conditions for both cell lines and brain cryosections. After primary antibody, samples 
were incubated with the appropriate secondary antibodies conjugated with one of 
the indicated fluorophores, Alexa fluor: 488, 555, 561 (Invitrogen) (dilution 1:200; 1 
hour RT). Early endosome were marked using Cell Light Early Endosome-RFP, 
BacMan 2.0 (Invitrogen) according to the procedure instruction. 
 
TUNEL ASSAY 
Detection of apoptosis was carried out by in situ TUNEL-assay (Click-iT® TUNEL 
Alexa Fluor® 633 Invitrogen-Life Technologies, Grand Island, NY, USA). TUNEL 
was performed according to the protocol provided by the manufacturer.  Briefly, 
after slide incubation (10 minutes at 37°C) in TdT reaction buffer, samples were 
incubated with TdT reaction mixture for 60 minutes at 37°C. After washes with 
PBS1x sections were washed with 3% BSA and 0.1% Triton® X-100 in PBS for 5 
minutes. The Click-iT® Plus TUNEL reaction cocktail was added to each slide for 30 
minutes at 37°C. 
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CONFOCAL MICROSCOPY AND IMAGES ANALYSIS 
Confocal microscopy was performed using a Leica TCS SP5 confocal microscope 
equipped with a resonant scanner (scan speed 8000 Hz) and a HCX PL APO 
63x/1.4 OIL objective, a HC PL FLUOTAR 10.0x0.30 DRY and a HC PL FLUOTAR 
20.0x0.50 DRY. Ag-nanoparticles (nps) were acquired in reflection mode upon 458 
nm excitation for in vitro cell experiments and upon 488nm excitation for in vivo 
experiments on brain cryosections. Syto blue was excited by the 458 nm laser line, 
nestin and phalloidin by the 488 nm line of an Argon laser, claudin, MMP-2 and ClC-
3 by the  561 nm laser line of a diode laser. Voxel size was established using  
Nyquist criteria. 
Intracellular Ag-nps quantification was carried out by 3D imaging analysis by means 
of IMARIS software (Bitplane, IMARIS) using the “Cells” function and the following 
set-up: cell detection/smooth filter =0,160; Background Subtraction, sphere 
diameter=20; Detect Vesicles,  Estimated Diameter= 240 nm; Vesicle Quality=18). 
Ag uptake analysis in vivo was performed using IMARIS software using the “Spots” 
function into a fixed area (6500 m2) for all fields, murine or human xenograft sites. 
MMP-2 and CLC-3 levels expression analysis was performed using Image J 
software. In brief, the central, the upper and the lower section of a 6 m z-stack was 
analyzed for each image. MMP-2 and ClC-3 Threshold mask was kept constant and 
using the tool “Analyze Particles”  area of MMP-2 and ClC-3 signal was calculated. 
MMP-2 and ClC-3 area was normalized on number of nuclei present in the slice 
analyzed.
 
WESTERN BLOTTING  
Approximately 2x105 U87MG cells were lysed in ice-cold  lysis buffer (100 mM 
Hepes, 2mM EDTA, 1% SDS) supplemented with protease inhibitors (ROCHE) and 
then stored at −80°C until used. Protein concentrations were determined using a 
BCA protein assay (Pierce). Equal amounts of protein (20 g) were loaded on 10% 
polyacrylamide gels and resolved on SDS-PAGE. Membranes were blocked (1 hour 
RT) with 5% milk in PBS/tween-20 0,1% (Sigma) and then probed (1 hour RT) with 
anti-human MMP-2 polyclonal rabbit antibody (1:1000) (Sigma), anti-human ClC-3 
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monoclonal rabbit antibody (1:1000) (Cell Signaling Technology, Beverly, MA,USA) 
and anti-human actin monoclonal mouse antibody (1:5000) (Sigma). Anti-rabbit 
and anti-mouse HRP-conjugated secondary antibodies (Pierce, Rockford, IL, USA) 
were employed at a dilution of 1:5000 for 1 RT. Bands were visualized by Bio-Rad 
Clarity western  ECL substrate (Biorad, Hercules, USA), and detected by ChemiDoc 
MP system (Biorad, Hercules, USA). All densitometric analyses were carried out 
using Image Lab  software version 5.1 (Biorad Hercules, USA). 
 
GELATIN ZYMOGRAPHY 
Supernatant from in vitro grown U87MG cells were eluted in Zymogram Sample 
Buffer (Biorad, Hercules, USA) according to producer instructions. Equal amount of 
each samples were loaded in Ready Gel® Zymogram Precast Gels (Biorad, 
Hercules, USA) and  electrophoresis was carried out at  fixed voltage of 90 V. The 
gels were washed  twice in distilled water  for 10’ and twice in  Zymogram 
Renaturation Buffer (Biorad, Hercules, USA) for 30’ and then incubated  for 6 hours 
at 37°C in Zymogram Development Buffer (Biorad, Hercules, USA). After 
incubation, gels were  stained with Bio-Safe Coomassie Stain (Biorad, Hercules, 
USA) for 2 hours. Gelatinolytic activity was detected as transparent bands on a blue 
background. Images were  acquired with chemidoc  system (Biorad, Hercules, 
USA). Densitometry analysis was performed with ImageJ Software. 
 
MTT ASSAY 
U87MG cells (5,000 cells/well) were plated in 96-well plates with 100 μl MEM 
medium. After 24 h cells were treated with increasing concentrations of Ag-nps 
encapsulated in the PNP nanovectors, whereas no treatment was done as positive 
proliferation control. At 72 h, 25 μl of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Sigma-Aldrich, St Louis, MO) was added directly 
to the cells followed by an additional 4 hours of incubation, then 100 μL of DMSO 
was added. The optical density of individual wells was measured at a wavelength of 
550 nm with the Sunrise apparatus (Tecan Group, Ltd, Mannedorf, Switzerland). All 
assays were performed in triplicate. 
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STATISTICS 
Data are presented as mean ± SE. If not indicated mean values were compared by 
the Student’s t test (two-tailed, non parametric). Statistics and fitting of experimental 
data were performed with Graph Pad Prism6. 
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3 Aim of the project 
Glioblastoma (GBM) is still an incurable disease, with a life expectancy of around 14 
months from the diagnosis. The cause of this negative prognosis is due to various 
factors including the presence of GBM staminal cells, and the high grade of 
invasivity, drugs resistance and recidivism. Another important factor leading to drugs 
failure is related to the anatomical position in which tumor develops: the brain. Brain 
vasculature is characterized by the presence of the BBB, which contributes to 
significantly impeding chemotherapics from reaching malignant cells scattered in the 
brain parenchyma. Niches of GBM cells can thus grow and lead to recidivism. So far, 
any treatment is ineffective in case of recidivism, and the impossibility of totally 
eradicating GBM with the current clinical approaches is a powerful motivation to 
trying to devise new strategies. Under this respect, nanotechnological devices 
(especially nanoparticles), have been suggested as innovative tools for the therapy 
and diagnosis of central nervous system diseases by increasing drug accumulation in 
cells and escaping the efflux mechanisms. Aim of this work was the assessment of 
the effectiveness of polymeric nanovectors, combined with radiotherapy, in reaching 
GBM tumor cells, in particular those in the peripheral tumor niches, and determining 
tumor growth inhibition. With the intent to quantify targeted nanovectors reaching 
tumor cells, and to track their localization, PLGA-b-PEG nanovectors conjugated to 
Chlorotoxin (CTX) and encapsulating silver nanoparticles (Ag-nps), visible with 
optical and confocal microscope imaging in reflection mode ( Ag-PNP-CTX), were 
employed. 
Specific goals were to evaluate: 
 
 Tumor-specific intracellular uptake, intracellular trafficking and endosomal 
escape of Ag-PNP-CTX nanovectors, with and without the radiation 
treatment.  
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 Ag-PNP-CTX nanovector quantification and biodistribution in the tumor, in 
the brain parenchyma, and in the peripheral organs after systemic 
administration in U87MG orthotopic xenografted mice. 
 The in vivo effects of ionizing radiations on the Ag-PNP-CTX distribution in 
the U87MG-tumor microenvironment and brain parenchyma.  
 The in vivo evaluation of synergistic therapeutic effect of radiations and Ag-
PNP-CTX nanovectors concomitantly administered.  
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4 Results 
4.1 Synthesis and Characterization of Ag-PNP-CTX 
nanovectors 
In order to assess the efficacy of polymeric nanocarriers to target GBM cells, poly 
(lactic)-co-glycolic)-co-poly ethylene glycol (PLGA-b-PEG) nanovectors (PNPs) 
conjugated to CTX (PNP-CTX) and encapsulating silver nanoparticles (Ag-nps) have 
been synthesized. 
Ag-PNP-CTX were prepared by Prof. Mauro Comes Franchini (Department of 
Industrial Chemistry “Toso Montanari”, University of Bologna, Italy.)  following a 
procedure already reported by Locatelli et al. 2012 (Figure 7 A) [170].  Firstly, Ag-nps 
were obtained through reduction of AgNO3 by glucose and NaOH in presence of 
polyvinylpyrrolidone (PVP) and later they were coated with the organic ligand 1 in 
order to obtain lipophilic nanoparticles (Ag-nps-1) [171]. Native Ag-nps present a 
hydrodynamic diameter of 35.4 ± 5.3 nm, which increased to 40 ± 7.6 nm after the 
coating with the organic ligand. A complete characterization of Ag-nps-1 was 
previously reported [172].  
 
 
 
 
 
 
Figure 7.  
(A) Schematic 
procedure for the 
synthesis of Ag-
PNP-CTX. 
Representative 
TEM image (B) 
DLS analysis (C) 
and ζ-potential 
analysis (D) of Ag-
PNP-CTX. 
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The nanoprecipitation method was exploited for this purpose and led to the 
entrapped of Ag-nps-1 in the inner core of the water-soluble PNP. Ag-PNP were then 
chemically conjugated onto the outer shell with the specific targeting agent CTX, thus 
giving Ag-PNP-CTX (Figure 7A). For this reaction the presence of carboxylic acid 
groups, derived from PEG chains, onto the surface of Ag-PNP was exploited for the 
formation of an amide bond with free-amino ending group of CTX absorption 
spectroscopy (AAS). PNP-CTX were characterized by Transmission Electron 
Microscopy (TEM, Figure 7B). Dynamic light scattering (DLS) revealed particles with 
diameter equal to 114 ± 2 nm, a low polydispersity index (PDI) (0.21 ± 0.01) ( Figure 
7C) and a negative ζ-potential (-31.6 mV) ( Figure 7D). Silver concentration was 
determined to be 3.81 mM by means of atomic Ag-nps-1 were then entrapped into 
PLGA-PEG polymeric nanoparticles (PNP). The overall Ag-PNP-CTX concentration 
was established by gravimetric analysis and found to be 8.87 mg/mL. 
4.2 Optical imaging and quantification of encapsulated Ag-
nps 
The use of Ag-nps has enabled us the use of confocal microscopy to visualize and 
quantify CTX-targeted nanovectors. The laser set in reflectant mode allowed Ag-nps 
detection (Figure 8 B). By means of this strategy, the cytoplasmatic amount of 
polymeric nanovectors has been quantified in 3 different human GBM-derived cell 
lines (U87MG, A172 and, T98G) after over-night incubation. 
 
 
Figure 8. Ag detection under laser reflection mode. (A-C) Pictures of Ag-nps: (A) bright 
field, (B) reflection mode (C) merge. Metal Ag-nps have been acquired in reflection mode 
upon 458 nm excitation and are shown in red. 
A B C
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In order to evaluate the tumor specific binding CTX-mediated, the amount of intake of 
functionalized nanovectors has been compared with not functionalized ones. 
Data on the exposure of CTX-functionalized and non-functionalized nanoparticles to 
the 3 GBM cell lines show that CTX is able to significantly increase PNPs uptake  
(Figure 9 A-E). 
 
 
Figure 9. Human-derived  GBM cell lines U87MG, A172 and T98G were incubated o/n in the 
presence of targeted (Ag-PNP-CTX) or non-targeted (Ag-PNP) nanovectors at Ag 
concentration of 100 M. The intracellular accumulation of Ag nanoparticles (Ag-nps) was 
determined by confocal laser scanning microscopy (A, B) and 3D imaging analysis 
performed by IMARIS software (C and D). (A) and (B) images represent the maximum 
projections of 20 optical sections of the cell labelled with Syto Blue 45® (green). Metal Ag-
nps have been acquired in reflection mode upon 458 nm excitation and are shown in red and 
DAPI signal for nuclei detection in blue. (C) and (D) computation 3D images of the peri-
nuclear region of cells in panel A and B respectively. (E) Intracellular Ag-nps quantification 
expressed as mean number of Ag-nps ± ES normalized on the cell surface (mm2). About 60 
cells / experimental group from 2 or 3 independent experiments were analyzed. Significance 
versus cells incubated with non-targeted nanovector (Ag-PNP): * p<0,02; **p<0,005.  
To exclude a CTX conformational change due to its binding to the polymeric core 
which could prevent CTX binding to its targets (MMP2 and ClC-3), a competitive 
assay has been carried out. The competition test was performed by pretreating GBM 
cells with increasing concentrations of native CTX peptide (from 500 ng to 1 ng/ml). 
Results showed a significantly lower, dose-dependent, PNPs uptake when cells were 
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incubated in the presence of native CTX peptide and CTX functionalized 
nanovectors. On the contrary, CTX native peptide did not modify the cellular uptake 
of non-targeted Ag-PNP nanovectors (Figure 10). These results strongly suggest that 
the covalent interaction between polymeric nanocarriers and CTX does not interfere 
with the ability of the peptide in recognizing its targets. 
 
 
Figure 10. Competitivity assay. Competitive inhibition of cellular uptake of Ag-PNP-CTX 
and Ag-PNP nanovectors in U87MG and A172 cells incubated with native CTX peptide at the 
indicated concentrations (ng/ml). Results are expressed as Ag-nps quantity ± ES normalized 
to the Ag-nps detected in cells incubated without native CTX peptide (first columns). 
Significance versus cells incubated in the absence of CTX peptide: U87MG * p=0,0334 ** 
p=0,0057 *** p=0,0004; A 172 ** p=0,0052. 
Therefore, the result of the competitivity assay can reasonably lead one to suppose 
that Ag-PNP-CTX endocytosis is a receptor mediated process. This type of 
endocytosis converges in endosomal/lysosomal pathway [173]. In order to assess 
the Ag-PNP-CTX ability to escape from endosomal compartment, the intracellular 
trafficking has been analyzed. 
Qualitative analysis showed no co-localization of Ag-nps with endosomal and 
lysosomal fluorescent markers (Figure 11) implying that CTX-nanovector cargo would 
be entirely released into the cytoplasm and not sequestered and/or degraded inside 
cellular organelles 
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Figure 11. Representative confocal microscopy images of single central plane of the whole z 
stack showing U87-MG cells incubated in the presence of Ag-PNP-CTX nanovectors. 
Intracellular endosomal and lysosomal compartments were identified using the specific-
associated markers Rab5a and LAMP-1 respectively. 
4.3 Radiations promote CTX-functionalized nanovectors 
accumulation in GBM tumors 
The in vivo tumor distribution of Ag-PNP-CTX nanovectors was evaluated in an 
orthotopic murine model of GBM. By means of stereotactic techniques, human 
U87MG has been transplanted in the right striatum of nude mice, one of the brain 
region in which GBM most frequently arise. To increase the infiltrative capacity, 7-10 
days before brain transplantation U87MG cells were grown in  MEM medium and 
low serum concentration (5% serum). Using an antibody directed against human 
nestin, a staminal marker overexpressed in glioma stem cells [174], it has been 
possible to distinguish human GBM cells from murine sourrounding cells (Figure 12). 
After 15 days from tumor transplantation, it has been possible to detect a relevant 
“central” tumor mass (figure 12 A) and infiltrative tumor niches within the healthy 
parenchyma at the periphery of the tumor (Figure 12 B). Outstandingly, it has been 
possible to detect single tumor cells spread into healthy tissue (Figure 12 C). In order 
to evaluate the amount of Ag-PNP-CTX able to reach the tumor, a single dose of 
Lamp1
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DAPI
Ag-nps
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PNPs has been administered intraperitoneally; after 20 hours from PNPs injection it 
has been possible to evaluate the presence of Ag-PNP-CTX at the tumor level. 
Similarly to in vitro, in vivo Ag-nps have been detected by confocal microscopy with 
the laser set in reflection mode. Quantification of Ag-nps carried out on brain 
cryosections showed a significantly higher level of accumulation in the GBM-tumor 
compared to healthy brain parenchyma, resulting in a mean number of Ag-PNP-CTX 
for each volume analyzed in every imagine (6500 m3) amounting to 26,36 (± 3,157 
ES) versus 0,7292 (± 0,1528 ES) (Figure 13 B) respectively. After 48h following 
nanoparticles injection, a wash-out of Ag-PNP-CTX has occurred (Figure 13 B): the 
mean number of nanoparticles is 7,291 (± 1,598 ES) versus 26, 36 at 24h (Figure 13 
B). The wash-out occurs also in the healthy murine portion of cerebral parenchyma, 
in which the mean number of Ag-PNP-CTX at 48h after injection has been found to 
be 0,5968 (± 0,1426 ES) (Figure 13 B). 
 
 
Figure 12. U87MG (5x104) cells were injected intracerebrally into athymic 6-8 weeks old 
male mice. After 2 weeks, animals were euthanized with intracardiac perfusion of PBS, 
followed by formaldehyde. GBM xenografts were detected by immune staining for human 
nestin (green). In blue is the DAPI signal for nuclei detection. (A) representative coronal 
section 15 days after tumor implantation; (B) and (C) magnified views of the indicated insets. 
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In order to mimic, to the greatest possible extent, the clinical conditions in which RT 
is employed, a radiation treatment was added to the experimental procedures in 
order to evaluate whether ionizing radiations could modulate Ag-PNP-CTX 
localization both at the tumor and healthy parenchyma level. A single 2 Gy 
administration has been performed 18h before Ag-PNP-CTX injection in the whole 
brain. 
 
Figure 13. In vivo accumulation of Ag-PNP-CTX nanovectors at tumor site assessed in 
U87MG orthotopic xenografts model. Fifteen days after implantation of tumor cells mice were 
subjected to total brain radiation treatment (2Gy). A parallel group of non-irradiated mice (0 
Gy) was considered as control. Ag-PNP-CTX were administered intraperitoneally 18 hours 
after radiations at a dose of 1mg/mouse. Animals were sacrificed 24 or 48 hours after 
nanovector injection. A) Representative images of renderings of U87MG tumor mass 
cryosections taken from irradiated (2 Gy) and non-irradiated (0 Gy) mice injected with Ag-
PNP-CTX (0Gy). Ag-nps have been acquired in reflection mode upon 488 nm excitation and 
are shown in red. Green areas show human nestin immunostaining; the nuclei are shown in 
blue (DAPI). B) Ag-nps quantification was performed in brain cryosections by confocal 
microscopy and IMARIS 3D imaging analysis.. (B) Ag-nps quantification is expressed as 
mean number of Ag-nps ± ES in a fixed volume of 6500 m3 . About 60 microscopy fields 
randomly taken from 4 mice in each experimental group were acquired and analyzed. 
Significance versus healthy brain tissue: ***p<0,0001.  
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Results from Ag-nps quantification indicated a further, noteworthy increased (about 4 
to 6 folds) amount of Ag-nps in U87MG-tumors from mice subjected to radiations 
compared to U87MG-tumors from non-irradiated mice (Figure 13B). The mean 
number of Ag-PNP-CTX in tumors irradiated 24h and 48h after nanovector  injection 
amounts to 87,86 (±10,46 ES) versus 163,9 (±8,584 ES) respectively (Figure 13 B). 
Interestingly, no wash-out of nanovectors has been shown to occur 48h after Ag-
PNP-CTX administration, indeed a higher quantity of Ag-nps has been detected 
compared to 24h after injection. Noteworthy, radiation treatment determined a non-
significant increase of Ag-nps accumulation in the healthy brain  
 
4.4 Radiations alter the blood-brain barrier allowing the 
targeting of GBM cells infiltrating healthy brain 
parenchyma  
Next aims have been to assess whether the lack of Ag-nps in the irradiated brain 
healthy parenchyma was due to the presence of an intact BBB, and to investigate the 
contribution of BBB disruption in increasing accumulation of Ag-PNP-CTX 
nanovectors in GBM tumors observed upon radiation treatment. To this end an 
immunostaing for Claudin-5, one of the most expressed brain endothelial tight 
junction proteins contributing to the maintenance of BBB integrity [175], was carried 
out. Claudin-5 pattern of expression have been determined by immunofluorescence 
on cryosections from normal and U87MG-implanted brain hemispheres treated and 
non-treated with radiations. Results indicated that a single dose of 2 Gy radiation 
caused alterations in claudin-5 distribution pattern, which was particularly evident in 
the healthy brain where the formation of gaps in brain vessel wall, caused by the 
opening of the tight junctions, was detectable (Figure 14 B). 
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Figure 14. In vivo BBB integrity.(A-D) Confocal images (maximum projections) of normal and 
tumor-associated blood vessels. Brain cryosections from U87MG-trasplanted mice previously 
irradiated (2Gy) or non-irradiated (0 Gy) were immunostained for claudin-5 (red) and human 
nestin (green). Nuclei were revealed by DAPI staining (blue). Lower panels are 
representative 3D rendering of selected regions of claudin-5 staining carried out by IMARIS 
software.  
In the proximity of the peripheral zone of the tumor we observed a normal claudin-5 
expression, suggestive of an intact BBB (Figure 14 D). No Ag-nps accumulation has 
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been observed in nestin-positive disperse cancer cells (Figure 15, left panel) located 
far from the tumor mass. After 2 Gy radiation treatment, however, in line with BBB 
permeabilization, Ag-nps could be detected in the isolated GBM cells branching into 
the healthy parenchyma  (Figure 15, right panel). 
 
 
Figure 15. Ag-PNP-CTX nanovector diffusion in peripheral tumor areas. Ag-nps and 
nestin co-localization in single cells present at the U87MG tumor periphery from non-
irradiated (0Gy, left panel)  and irradiated (2Gy, right panel) mice injected with Ag-PNP-CTX. 
The isolated cells, labeled with antibodies recognizing human nestin (in green), is a tumor 
cell which infiltrates the healthy mice tissue, which is negative for the human nestin antibody.  
In the bright field Ag-nps are visible as black dots. In the lowers panel representative bright 
field images acquired by differential interference contrast (DIC) of cryosections of non-
irradiated (0 Gy) and irradiated (2 Gy) peripheral tumor tissues from U87MG orthotopic 
xenografts inoculated with Ag-PNP-CTX nanovectors. Ag-nps are visible as black spots. 
Lateral panels are magnified views of the indicated insets. Ag-nps have been acquired in 
reflection mode upon 488 nm excitation and are shown in red. 
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4.5 Radiation Augments Specific Cellular Uptake and 
Intracellular Localization by inducing MMP-2 and ClC-3 
overexpression  
In order to understand the effective role of x rays on increasing Ag-PNP-CTX in GBM 
cells, in vitro experiments have been carried out. The amount of PNPs has been 
evaluated after a single dose of 2 Gy on two human GBM cell lines, U87MG and 
T98G.  
Notably, while irradiated cells, both U87MG and T98G lines, incubated in the 
presence of Ag-PNP-CTX displayed a significant increase in intracellular Ag-nps, no 
variations were observed in either cell lines when incubated in the presence of non-
targeted Ag-PNP nanovectors  (Figure 16 A and 16 B). Given that CTX is the ligand 
for MMP-2 and ClC-3, which are highly expressed in human gliomas [166,169], the 
expression level of these molecules in non-irradiated and irradiated was compared. 
RT is known to induce MMP-2 expression [176-178] but no data are available yet on 
ClC-3 expression after radiation treatment.  
Western-blot results showed an up-regulation of MMP-2 and ClC-3 levels of 
expression induced by radiations (Figure 16 B). The effect was particularly evident 
for CIC-3. Similarly, simultaneous microscopy detection of MMP-2 or ClC-3 and Ag-
nps in non-irradiated and irradiated U87MG cells confirmed that radiations increase 
MMP-2 and ClC-3 levels of expression, which correlate with a higher amount of 
internalized Ag-nps (Figure 16 A and D).   
Notably, the increased expression of MMP-2 and ClC-3 was observed also in vivo, in 
irradiated U87MG xenografts (Figure 17). 
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Figure 16.  Radiation induced CTX-nanovector intracellular uptake, MMP-2 and ClC-3 
expression. (A) Intracellular Ag-nps quantification in irradiated (2 Gy) and non-irradiated (0 
Gy) U87MG or TG98 cells incubated overnight in the presence of Ag-PNP or Ag-PNP-CTX. 
Results are expressed as Ag-nps quantity ± ES normalized to the Ag-nps detected in non-
irradiated cells incubated with Ag-PNP(0 Gy Ag-PNP, first column). For analysis details see 
also Supplementary figure 1. Significance versus non-irradiated cells: * p=0,0117. (B) 
Western-blot analysis of MMP-2 and ClC-3 expression in irradiated and non-irradiated 
U87MG cells. One representative experiment out of 4 performed is reported. Levels of β-
actin are reported as control for protein loading. (C) Densitometry analysis of western-blot 
bands (panel B) performed by Image-Lab software. Results normalized on corresponding β-
actin. (D) Ag-nps (red) and MMP-2 or ClC-3 (green) signals in irradiated (2Gy) and non-
irradiated (0 Gy) U87MG cells shown as maximum projections of 6 optical sections. In blue is 
the nuclear staining (DAPI).  Cell borders were defined by phalloidin staining (gray). 
B
0
1
2
3
*A
2 Gy
0 Gy
Ag-PNP Ag-PNP-CTX
In
tr
a
c
e
llu
la
r 
A
g
-n
p
s
 
F
o
ld
 i
n
c
re
a
s
e
Ag-PNP Ag-PNP-CTX
2 Gy
0 Gy
U87MG T98G
0 
G
y 
N
p
2 
G
y 
N
P
0 
G
y 
C
TX
2 
G
y 
C
TX
0
2
4
6 **
0 Gy 2 Gy
MMP2
Ag-nps
ClC3
0 Gy 2 Gy
Ag-nps
-actin
0 Gy 2 Gy
ClC-3
MMP-2
In
te
g
ra
te
d
  
D
e
n
s
it
y 0 Gy
2 Gy
0
1
2
3
Legend
Legend
MMP-2 ClC-3
0 
G
y 
M
M
P
2
2 
G
y 
u8
7 
M
M
P
2
0 
G
y 
C
LC
3
2 
G
y 
U
87
M
G
 C
LC
3
0
1
2
3
4
5
*
D
  
44 
 
 
 
Figure 17. In vivo MMP-2 and ClC3- expression in  U87MG xenograft before and after 
radiations. (A-C) Representative confocal images of brain cryosections from U87MG-
trasplanted mice previously irradiated (2Gy) or non-irradiated (0 Gy) and immunostained for 
human MMP-2 or ClC-3 (red) and nestin (green). Nuclei were revealed by DAPI staining 
(blue). (B-D) In vivo MMP-2 and ClC-3 level of expression quantification in U87MG 
xenographs 48 and 72 hours after x-rays treatment. Results are expressed as increased 
mean MMP-2 and/or ClC-3 fluorescent area respect to non-irradiated samples (0 Gy) ± ES. 
About 15 microscopy fields for each experimental condition were randomly acquired and 
analyzed by ImageJ software. For each single microscopy field analyzed MMP-2 and/or ClC-
3 fluorescent area was normalized on nuclei number. MMP-2 significance versus non–
irradiated tumor cells *  p=0,0119; ***p=0,0005. 
4.6  CTX-targeted nanovectors act as inhibitor of MMP-2 
enzymatic activity  
MMP-2, as pointed out before, is a component involved in ECM degradation, in the 
progression, invasion, and metastasis of malignant lesions [179]. Notably, increase of 
metastatic tumor activity has been described as a consequence of RT, which 
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enhances pro-MMP-2 expression [177]. Therefore, whether the binding of CTX-
nanovectors to MMP-2 could interfere with its catalytic activity was investigated. 
 
Figure 18. Inhibition of MMP-2 catalytic activity in U87MG cells induced by Ag-PNP-
CTX nanovectors. U87MG cells previously irradiated (2Gy)  were incubated in the presence 
of Ag-PNP or Ag-PNP-CTX nanovectors (100 uM for 16 hours). Inhibition of MMP-2 catalytic 
activity was evaluated by zymography. (A) Representative zymography  of one out of 2 
independent experiments performed. (B) Densitometry analysis of zimography bands. 
Results are expressed as mean values from  2 independent experiments normalized to non-
irradiated cells (0 Gy) ± ES. Statistical significance was evaluated by One-way ANOVA. 
Significance versus irradiated cells: *p<0,05. 
MMP-2 activity was evaluated by zimography. After  a single dose of x rays (2 Gy)  
U87MG cells were incubated O/N  with non-targeted Ag-PNP and targeted Ag-PNP-
CTX nanovectors. Remarkably, MMP-2 catalytic activity was inhibited of about  50% 
exclusively in cells incubated with targeted Ag-PNP-CTX nanovectors while no 
changes were observed in irradiated cells incubated with non-targeted Ag-PNP 
nanovectors (Figure 18). Thus, CTX-PNP nanovectors could attain synergistic dual 
therapeutic effects, tumor-specific intracellular drug-delivery and inhibition of MMP-2 
activity. 
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4.7 In vivo biodistribution of encapsulated Ag-nps 
In addition to the Ag-nps accumulation in the brain, Ag-PNP-CTX nanovector 
biodistribution in peripheral organs was assessed. After Ag-PNP-CTX intra peritoneal 
injection, animals have been sacrificed at selected time points (24h and 48h after 
injection) and several tissues including liver, spleen, lung, heart and kidney have 
been examined in order to quantify the amount of Ag-nps by Inductively Coupled 
Plasma Mass Spectrometry (ICP-MS). As expected, Ag-PNP-CTX particles have 
been mostly found in the reticuloendothelial system (RES) organs (liver, ~80%, and 
spleen, ~ 4% of the injected Ag-nps). Only 2 % of the injected Ag-nps have been 
found in the lung and a remarkable washout has been observed at 48 hours after 
nanovector delivery. A very low number of Ag-PNP-CTX nanovectors have been 
found in the kidney and in the hearth (Figure 19). 
 
Figure 19. Ag-NP-CTX biodistribution in peripheral organs was evaluated in fresh, non-fixed 
organs from non-irradiated (0 Gy) and irradiated (2 Gy) U87MG orthotopic transplanted mice 
(4 mice /experimental group for a total of 16 mice analyzed). Fifteen days after implantation 
of tumor cells, Ag-PNP-CTX were administered intraperitoneally at a dose of 1mg/mouse. 
Animals were sacrificed 24 or 48 hours after nanovector injection. Ag-nps quantification was 
assessed by Inductively Coupled Plasma Mass Spectrometry (ICP-MS) (NEOTRON, 
Modena, Italy). Results are expressed as amount of Ag detected in 1 mg of the indicated 
organ ± SE. 
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4.8 Radiations enhance Ag-PNP-CTX cytotoxic activity 
against U87MG GBM human cell line 
Recently, the possibility of using Ag-nps as antitumoral agents for GBM, either alone  
[172, 180] or in synergy with other kinds of drugs [172], after entrapment in 
biocompatible PNPs has been explored.  
Thus, a possible synergistic effect of a 2Gy radiation treatment combined with Ag-
PNP-CTX administration on U87MG cell growth and viability was investigated. 
Irradiated and non-irradiated U87MG cells have been incubated with different Ag-
PNP-CTX nanovectors concentration for 72h; thereafter, cell viability has been 
assessed by MTT test. Other U87MG cells have been treated with either nanovectors 
without Ag-nps (PNP-CTX), in order to assess polymer and CTX toxicity, or non-
targeted nanovectors (Ag-PNP), as a control. As expected, no cellular toxicity has 
been observed by incubating U87MG cells with empty PNP-CTX nanovectors, while 
the presence of CTX on the Ag-PNP surface has been found to trigger a dose-
dependent inhibition of cell growth induced by the encapsulated Ag-nps. More 
remarkably, a synergic reduction of U87MG cell viability has been observed when 2 
Gy irradiation is delivered before Ag-PNP-CTX incubation. Pro-apoptotic synergic 
effects have been detected also in vivo in U87MG-transplanted mice. The detection 
and quantification of apoptotic bodies by in situ terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL) assay has shown a significant increase in the 
amount of apoptotic bodies in irradiated U87MG xenografts and of Ag-PNP-CTX 
nanovectors vs. U87MG xenografts treated with CTX nanovectors or exposed to 
radiations as single agents (Figure 20 B). Additional support to the TUNEL results 
have been provided by bioluminescence imaging (BLI) analysis carried out in 
luciferase-transfected U87MG (U87MGluc2) xenografts in order to monitor tumor 
growth over the treatment period (Figure 20 C and D). Eleven days after U87MGluc2 
cells implantation (T=0), mice have been divided into 4 groups: untreated mice; mice 
treated with radiations (2Gy, single dose); mice treated with serial injections of Ag-
PNP-CTX single agent (2 doses of 1mg dry matter per mouse, followed by 2 doses of 
0,5 mg dry matter per mouse; interval time: 48-72 hours); mice concomitantly treated 
with radiations and Ag-PNP-CTX. 
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Figure 20. Effect of Ag-nps entrapped into PNP-CTX nanovectors on irradiated (2 Gy) and 
non-irradiated U87MG cells and tumors viability. (A) Upon treatment with the indicated 
nanovectors cell survival fraction was measured by MTT assay. Cells were exposed to 
increasing concentrations of Ag-nps for 72 hours The obtained relative values were 
normalized to the values from the corresponding untreated cells and are shown as 
percentage survival. Results are expressed as mean percentage of 3 independent 
experiments performed in triplicates ± SD. (B) In situ detection of apoptosis by DAPI/TUNEL 
staining and quantification of apoptotic bodies (1-5 mm size) in U87MG cryosections from 
non-irradiated and irradiated  (2 Gy) mice injected with Ag-PNP-CTX nanovectors. Animals 
were sacrificed 48 hours after nanovector injection. Four mice/experimental group were 
analyzed. Results are expressed as mean values normalized to CTR values ± ES. (C) 
Luciferase imaging of representative mice: untreated (CTRL, 4 mice);  injected with Ag-PNP-
CTX nanovectors  as single agent (2 doses of 1mg/mouse followed by 2 doses of 0,5 
mg/mouse, administration interval: 48-72 hours, 5 mice);  irradiated (2 Gy single dose, 6 
mice); treated with radiations and concomitant Ag-PNP-CTX nanovectors (6 mice). 
Treatments started 11 days after U87MGluc2 cell implantation (T0=D11). (D) Tumor growth 
during 11 days of observation measured by area detected setting automatic ROI (50%). 
Results are expressed as mean values normalized to T0 values ± SE. Statistical significance 
was evaluated by Paired T test. Significance: *p=0,0177. 
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As illustrated in Figure 20 C, which shows representative images of single animals 
from each experimental group, and 20 D, which shows the quantitative analysis of 
the tumor regions, synergic radiation and CTX-nanovectors treatment has inhibited 
tumor growth and progression. No inhibitory effect has been observed in mice treated 
with either radiations or Ag-PNP-CTX only. 
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5 Discussion 
The aim of this work has been to evaluate the efficacy of nanotechnologies for the 
treatment of GBM. In particular, the capacity of Ag-PNP-CTX nanovectors to target 
GBM cells has been assessed in vitro and in vivo.  
 
The PLGA-b-PEG core polymer has been chosen for two main reasons. First it has 
been approved by the Food and Drug Administration (FDA) for human medical usage 
in view of its good biocompatibility and low toxicity. Indeed, PLGA-b-PEG is already 
employed in clinical trials [181]. Second reason concerns the distinctive chemical-
physical features of this material. One of these features is the versatility of PLGA-b-
PEG nanocarriers: they can be loaded with many types of substances such as 
different drugs and/or cytotoxic molecules including nucleic acids. These nanovectors 
protect their contents, thus increasing payload half-life, particularly important for the 
in vivo efficacy. Another advantage is that they do not activate inflammatory 
responses, such as opsonization [182]. Due to their chemical composition, PLGA-b-
PEG allows nanovectors to release its content gradually [183]. 
 
In this work the polymeric core (PNP) has been loaded with silver nanoparticles (Ag-
nps). Taking advantage of the high contrast provided by Ag-nps they have been used 
as contrast agents for optical/confocal microscopy detection and imaging of PNPs. In 
this way, the main advantage is that nanovectors can be visualized without adding 
fluorescent dyes, thus avoiding chemical modification of the external shell of the 
nanocarriers, and the subsequent alteration in PNP behavior in the body. 
Due to the high stability of Ag-nps and the absence of photobleaching phenomena, 
Ag-nps represent a very efficient imaging tool for single-cell analysis, characterized 
by extreme precision and quality with respect to standard fluorescence-based 
techniques. The light reflection property of Ag-nps allows one to acquire Ag-nps 
signals with the laser set in reflection mode, without affecting the freedom of choice 
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of fluorescent markers when the localization of different proteins has to be studied in 
multicolor experiments. Moreover a fluorescent moiety, linked or adsorbed onto the 
external surface, may undergo leakage phenomena from the nanosystem once in the 
body environment, which can lead in turn to unspecific fluorescence detection in not 
really targeted cells; on the contrary, Ag-nps being strongly entrapped inside the 
polymeric matrix, are stable and not subjected to this inconvenience. As a general 
rule, the use of Ag-nps-loaded nanovectors may represent a valuable tool to 
measure the delivery potential and/or to define the proper administration route and 
scheduling of drug-loaded nanovectors of interest. Therefore, the use of precise and 
quantitative methods to track systemically injected nanovectors is of crucial relevance 
to evaluate and foresee their potential therapeutic efficacy. Indeed, Ag-nps enabled 
the localization of Ag-PNP-CTX nanovectors in the intracellular compartment (such 
as the endosomes and lysosomes), and to study in vivo tumor localization at single-
cell level.  
 
Another advantage of using PLGA-b-PEG nanovectors concerns the  possibility  of 
functionalizing the polymeric surface with peptides able to recognize specific targets. 
This contributes to significantly increase the amount of uptake, and, in principle, to 
deliver drug-loaded nanovectors towards the desired target, thus decreasing the side 
effects with respect to a free drug. 
 
The experiments reported in this work have demonstrated the effectiveness of CTX 
in increasing Ag-nps uptake in GBM cells in vitro. The competitivity assay has shown 
that the binding between CTX and the polymeric core nanoparticle does not 
compromise the possibility of recognition of CTX on its targets, MMP2 and ClC-3 
known to be overexpressed in high grade glioma cells [41, 73]. 
This kind of nanovectors can be functionalized with a wide variety of ligands. In 
principle, one could even functionalize with more than one ligand at the same time, 
thus making them selective to different targets and multi-functional. This strategy 
could improve the effectiveness of the therapeutic strategy, especially in view of the 
high heterogeneity of GBM cells and the fact that different targets are expressed on 
the surface of GBM cells differing from one other in the degree of differentiation 
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[184]. The same nanovectors could then target a wide variety of GBM cells. Due to 
the fact that its intracellular uptake is receptor-mediated, CTX-nanovectors might be 
able to bypass the obstacle imposed by multi-drug resistance proteins situated on the 
cell membrane and that concur to decrease the amount of drug available in the 
cytoplasm and the efficacy of the drugs. 
 
The CTX-mediated endocytosis of nanovectors is receptor-dependent. In some 
cases, the vesicles resulting from endocytosis converge in lysosomes [173]. Due to 
the particular features of the polymer, and especially by virtue of the z-potential being 
very far from 0, the nanovector can eventually escape from the endo-lysosomal 
pathway, thus preventing its content from being degraded by the lysosomal enzymes 
[185,186]. This phenomenon, called endosomal/lysosomal escape can be produced 
by several mechanisms depending on the chemical nature of the nanovector [187]. 
One of the mechanisms reported in the literature which might provide the basis to 
explain the escape of the Ag-PNP-CTX nanovectors is the “proton sponge effect” 
[188]. the hypothesis is that the presence of the negatively charged nanoparticles (-
potential = -30mV) is balanced by the influx of positive charges (H+) into the 
endosome. This influx of protons causes an influx of Cl- which balances the excess 
of positive charge. The consequent influx of water, together with the destabilization of 
the endosome membrane caused by the negative charge of the nanoparticle, breaks 
the endosome causing release of its content in the cytoplasm. 
 
The presence of the BBB contributes to the current GBM therapeutic constraints by 
limiting the amount of chemotherapeutics reaching disperse tumor cells infiltrating the 
brain parenchyma.  
Part of this work has been devoted to assess whether nanotechnologies can help to 
overcome this problem. While the integrity of the BBB would guarantee reduced 
nanovectors off-target brain toxicity, it makes infiltrating and metastatic GBM cells 
inaccessible to nanovectors. It is worth noting that CTX, while is able to recognize 
with high affinity GBM cells, it is not an agent for BBB crossing, thus nanovector brain 
biodistribution could be limited by the presence of this barrier. As radiotherapy RT is 
a mainstay of GBM therapy regimens [15, 20] and is known to affect BBB 
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permeability [189, 190] the effects of radiations on Ag-PNP-CTX tumor accumulation 
have been assessed. 
To mimic to the greatest possible extent one of the current clinical RT protocols used 
to treat GBM patients (60 Gy delivered in fractions of 2 Gy) [20] we have chosen 2 
Gy as a standard experimental RT dosage. As hypothesized, upon radiations a 
significantly higher quantity of Ag-nps was observed in the tumor area. An increased 
accumulation was observed at 48 hours from Ag-PNP-CTX injection compared to 24 
hours, suggesting an enhanced permeability and retention (EPR) effect, which may 
prevent nanovectors wash-out and facilitate their accumulation. Interestingly, 
radiation treatment has been shown not to determine an increased accumulation of 
Ag-nps in the healthy brain parenchyma. 
 
As expected, in the proximity of the peripheral zone of the tumor we have observed a 
normal claudin-5 expression, suggestive of an intact BBB. Indeed, no Ag-nps 
accumulation has been found in the nestin-positive cells found in the tumor periphery 
and/or far from the tumor mass. However, after 2 Gy radiation treatment – which is 
known to increase BBB permeability – Ag-nps have been detected in the isolated 
GBM cells branching into the healthy parenchyma 
 
Differently from healthy brain, the tumorigenic GBM microenvironment promotes neo-
angiogenesis and disruption of BBB integrity [191]. The permeabilization of the BBB 
in the tumor area allows in fact penetration and retention of  Ag-nps within the non-
irradiated GBM-tumor, although at a lesser extent compared to the irradiated one. 
Even though low doses of radiations have been shown to be enough to determine in 
vivo tight junction deregulation (Figure 5B), the presence of a compromised BBB 
didn’t allow significant accumulation of Ag-nps in irradiated healthy brain parenchyma 
(Figure 4). This is consistent with the presence, surrounding the brain vessels, of 
pericytes and astrocytes that contribute to hindering the passive passage of 
nanovectors [192]. Furthermore, the interstitial fluid pressure and the width of the 
extracellular space impact on nanovector access and penetration within the healthy 
parenchyma. It is conceivable that extra-cellular matrix (ECM) components would 
physically restrict the motion of nanovector in convection through the extracellular 
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space. It was previously reported that the extracellular spaces in normal brain are 
between 38 and 64 nm [163]. Therefore, 100nm-sized CTX-nanovectors, likewise the 
ones used in this study, would hardly diffuse and accumulate in healthy brain tissue. 
The lack of Ag-nps accumulation in infiltrating GBM cells in the absence of radiation 
treatment is compatible with the possibility that, besides favoring permeabilization of 
the BBB, ionizing radiations, by enhancing the expression of cellular proteases, 
including MMP-2, play a crucial role in degradation and remodeling of brain ECM 
thereby facilitating extravasation, convective movements and diffusion of CTX-
nanovectors.  
This is relevant in the clinical setting, where RT is applied not only to the tumor area 
but extended to a 2 cm surrounding margins where invading GBM stem-like cells 
escape to surgery and survive to RT [193,194]. Thus the concomitant use of CTX-
nanovectors during RT should facilitate and enhance drug-delivery to the invading 
and metastatic GBM cells that are the responsible for the majority of the recurrences. 
 
Even though the results obtained in vitro indicated a noteworthy increase of ClC-3 
expression compared to MMP-2 after radiation treatment, the in vivo ClC-3 and 
MMP-2 levels were comparable, suggesting an equivalent contribution for 
nanovectors cellular uptake and internalization. Indeed the assessment of MMP2 
activity in presence of CTX shows that the process of recognizing and internalizing 
CTX-conjugated nanoparticles leads to a 50% decrease of the proteolic activity, thus 
suggesting that the use of CTX can have the dual role of directing nanovectors 
towards the target and of decreasing the side effects related to radiation-induced 
invasivity. It is reasonable to suppose that CTX conjugated to the polymer can also 
interfere with ClC-3 activity, by inhibiting the contribution of this channel to cellular 
motility as it has been already shown in studies on free CTX [76, 195]. 
 
 
As polymeric material is used in some clinical trials [181] we have tried to check 
whether our system is effective against tumor growth. Moderate toxicity of Ag has 
been detected, consistently with the literature [172, 180]. The experiments carried out 
to assess the toxicity of Ag-PNP-CTX in vitro and in vivo have provided a proof-of-
  
55 
 
concept of the therapeutic validity of a combination strategy based on radiation 
therapy and CTX-targeted polymeric nanovectors, which is expected to strengthen 
the anti-tumor efficacy of any cytotoxic molecules entrapped into PNP-CTX 
nanovectors. 
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6 Conclusions 
In this work, a nano-technological strategy has been proposed for the management 
of GBM that addresses two relevant obstacles to effective therapy:  
1) the infiltrative nature of GBM;  
2) the increase of MMP-2 expression following radiotherapy.  
Overall the results showed that (1) although large and advanced GBM tumors disrupt 
the BBB sufficiently to allow extravasation of functionalized nanocarriers, low dose 
RT (2 Gy, single dose), by inducing overexpression of proteases such as MMP-2, 
which also represent CTX molecular targets together with the chloride channel ClC-3, 
give tumor ECM more porous and permeable to nanovectors, determining their 
significant enhanced accumulation; (2) differently from the main tumor mass, 
peripheral GBM tumor niches, where more tumorigenic and invading cells reside, are 
accessible to engineered nanocarriers exclusively upon radiation treatment;  (3) low 
dose RT is not enough to determine complete BBB disruption preventing nanocarrier 
accumulation in irradiated healthy brain parenchyma; (4) CTX surface 
functionalization, besides causing an increased cellular uptake of CTX-targeted 
nanovectors, inhibits MMP-2 enzymatic activity.  
 
Having demonstrated that an increased nanovectors accumulation and retention can 
be achieved at significant lower dose of RT (2 Gy), a strong and relevant rationale 
has been provide for the development of therapeutic strategies able to target 
tumorigenic and invading GBM cells based on the concomitant administration of RT 
and CTX-targeted nanovectors. A synergistic therapeutic effect could start from the 
first fractionated RT dose. Considering that radiations induce the expression of 
molecules such as MMPs that favor tumor invasion and metastases, the concomitant 
administration of RT and CTX-targeted nanovectors could represent a significant 
step forward to GBM management. Indeed, the synergistic effect of CTX-targeted 
would result from a significant increased accumulation of nanovector therapeutic 
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cargo inside GBM cells and from the inhibition of approximately 50 % of MMP-2 
catalytic activity. These results enable one to conclude that CTX-targeted 
nanovectors as adjuvants to RT may increase the efficacy of anti-GBM therapies.  
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